Side Effects of Pitavastatin
Pitavastatin is generally well-tolerated with a favorable safety profile, but like all statins, it carries risks of muscle-related symptoms (myalgia 3.1% at 4 mg dose), gastrointestinal effects (constipation 2.2%, diarrhea 1.9%), and rare but serious complications including rhabdomyolysis, immune-mediated necrotizing myopathy, and hepatic dysfunction. 1
Common Adverse Effects (≥2% incidence)
Based on FDA labeling from clinical trials of 3,291 patients, the most frequent side effects at the 4 mg dose include:
- Myalgia: 3.1% (dose-dependent: 1.9% at 1 mg, 2.8% at 2 mg)
- Constipation: 2.2%
- Diarrhea: 1.9%
- Back pain: 1.4%
- Pain in extremities: 0.9%
Additional commonly reported effects include arthralgia, headache, influenza, and nasopharyngitis 1. Discontinuation rates due to adverse effects were low: 3.9% (1 mg), 3.3% (2 mg), and 3.7% (4 mg), with elevated creatine phosphokinase (0.6%) and myalgia (0.5%) being the most common reasons for stopping the 4 mg dose 1.
Serious Adverse Effects
Myopathy and Rhabdomyolysis
Risk is extremely rare but potentially fatal. Patients must be instructed to immediately report muscle pain, weakness, or brown urine 2. The Canadian guideline notes that severe myopathy occurs in approximately 0.08-0.09% of statin users 3. Risk factors include:
- Higher doses
- Concurrent use of fibrates (especially gemfibrozil)
- Drug interactions affecting metabolism
- Renal impairment
- Advanced age
Critical caveat: Routine CK monitoring is not recommended in asymptomatic patients; only check CK when symptoms develop 2.
Immune-Mediated Necrotizing Myopathy (IMNM)
A rare autoimmune condition characterized by:
- Proximal muscle weakness
- Persistently elevated CK despite statin discontinuation
- Positive anti-HMG CoA reductase antibody
- Requires immunosuppressive therapy 1
Hepatic Effects
- Transaminase elevations: Generally transient and asymptomatic
- Hepatic failure: Rare postmarketing reports (fatal and non-fatal)
- Risk factors: Heavy alcohol consumption, pre-existing liver disease
- Monitoring approach: The 2013 Canadian guideline explicitly states that periodic liver enzyme monitoring does not effectively detect or prevent serious liver injury, justifying discontinuation of routine serial monitoring 3
Contraindication: Acute liver failure or decompensated cirrhosis 1
Metabolic Effects
Diabetes Risk
Pitavastatin may have a more favorable metabolic profile compared to other statins. While increases in HbA1c and fasting glucose have been reported 1, recent evidence suggests pitavastatin may actually be protective against new-onset diabetes 4. In a UAE cohort study, only 1.0% developed new-onset diabetes after 6 weeks 5, which is notably lower than rates seen with rosuvastatin and atorvastatin 4.
Renal Effects
The 2013 Canadian guideline addresses concerns about high-potency statins and acute kidney injury (AKI). While one large retrospective study found 34% increased AKI risk with high-potency statins in non-CKD patients within 120 days of initiation 3, pitavastatin specifically was noted to be "safe and well tolerated in subjects with severe renal impairment not using hemodialysis" 3.
Postmarketing Adverse Reactions
Rare but documented effects include:
Neurological:
- Peripheral neuropathy, hypoesthesia
- Cognitive impairment (memory loss, confusion) - generally reversible upon discontinuation
- New onset or exacerbation of myasthenia gravis 1
Other systems:
- Interstitial lung disease
- Erectile dysfunction
- Psychiatric effects (insomnia, depression)
- Hypersensitivity reactions (rash, pruritus, urticaria, angioedema)
- Lichen planus 1
Laboratory Abnormalities
Elevations may occur in:
- Creatine phosphokinase
- Transaminases (ALT/AST)
- Alkaline phosphatase
- Bilirubin
- Glucose 1
Special Populations
HIV-infected patients: In a 52-week trial of 126 HIV patients on antiretroviral therapy, the safety profile was consistent with general population studies. Only 0.8% had CK >10× ULN (resolved spontaneously), and 3% had ALT 3-5× ULN without requiring discontinuation 1. The REPRIEVE trial demonstrated cardiovascular benefit with acceptable safety in this population 6.
Pediatric patients (≥8 years with HeFH): Safety profile similar to adults 1.
Comparative Safety Considerations
Pitavastatin has distinct advantages:
- Minimal cytochrome P-450 metabolism reduces drug-drug interactions compared to atorvastatin, simvastatin, and lovastatin 7, 8
- Better myopathy profile than some other statins 8
- May have lower diabetes risk than rosuvastatin and atorvastatin 4
The 2002 ACC/AHA/NHLBI advisory noted that all currently marketed statins (excluding the withdrawn cerivastatin) have similar rates of severe myopathy and should be considered equivalent in this risk 2.